

RESEARCH MONOGRAPH . COMPOUND PROFILE

BPAP

A benzofuran-containing synthetic enhancer substance developed by Knoll and colleagues as the most potent known monoaminergic activity enhancer, selectively amplifying impulse-dependent release of dopamine, norepinephrine, and serotonin in the brain without monoamine oxidase inhibition or amphetamine-like releasing activity.

DOCUMENT	KDC-MN-1536
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Tryptamine-derived synthetic monoaminergic activity enhancer (MAE) with catecholaminergic and serotonergic impulse-propagation-mediated release enhancement and TAAR1 agonism

ABSTRACT

(-)-1-(Benzofuran-2-yl)-2-propylaminopentane, designated (-)BPAP and also known by the developmental code FPFS-1169, is a synthetic monoaminergic activity enhancer (MAE) structurally derived from phenylpropylaminopentane (PPAP) through replacement of the phenyl ring with a benzofuran heterocycle. First described by Jozsef Knoll and colleagues in 1999, BPAP represents the most potent synthetic enhancer substance characterized to date, approximately 130-fold more potent than selegiline ((-)-deprenyl) in antagonizing tetrabenazine-induced performance inhibition in the rat shuttle box paradigm, and is the first enhancer substance to augment serotonergic neurotransmission in addition to the catecholaminergic enhancement shared with selegiline and PPAP. The compound selectively amplifies the quantity of dopamine, norepinephrine, and serotonin released per nerve impulse from monoaminergic neurons without inducing spontaneous (impulse-independent) neurotransmitter release, a pharmacological property that distinguishes it fundamentally from amphetamine-type releasing agents and from monoamine oxidase inhibitors. The mechanism of the enhancer effect has been attributed, on the basis of pharmacological antagonism studies using the selective antagonist EPPTB, to agonism at trace amine-associated receptor 1 (TAAR1), which triggers PKC-dependent phosphorylation of SNARE complex proteins and vesicular monoamine transporter 2 (VMAT2), thereby increasing vesicular monoamine accumulation and exocytotic release. At substantially higher concentrations, BPAP also inhibits monoamine reuptake (predominantly dopamine and norepinephrine), though this activity is not

considered pharmacologically relevant at the low nanogram-per-milliliter concentrations that produce the enhancer effect. In preclinical pharmacology, BPAP has demonstrated neuroprotective activity against N-methyl(R)salsolinol-induced apoptosis in human dopaminergic SH-SY5Y neuroblastoma cells through stabilization of mitochondrial membrane potential and upregulation of anti-apoptotic Bcl-2 protein expression. The compound upregulates synthesis and secretion of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) in cultured mouse astrocytes, with NGF secretion increased up to 120-fold over control at optimal concentrations. In longevity studies conducted by Knoll and Miklya, subcutaneous administration of BPAP at 0.0001 mg/kg three times weekly from the 10th week of life significantly extended lifespan in male Wistar rats ($P < 0.02$) and suppressed spontaneous fibromyxosarcoma manifestation from 50 percent (saline controls) to 20 percent ($P < 0.001$). Pharmacokinetic characterization in rats indicates oral bioavailability with peak plasma levels at 30 to 60 minutes, a secondary peak at approximately 4 hours consistent with enterohepatic recirculation, a terminal elimination half-life of 5.5 to 5.8 hours, blood-brain barrier penetration with distribution to multiple brain regions, and predominantly urinary excretion with greater than 90 percent recovery in excreta within 72 hours. No human clinical trials have been conducted with BPAP as of the date of this monograph. The compound remains an investigational research tool with potential therapeutic relevance to neurodegenerative disease (Parkinson's disease, Alzheimer's disease), depression, and age-related cognitive decline. This monograph reviews the chemistry, synthesis, and stereochemistry of BPAP; the enhancer pharmacology in molecular and

neurochemical detail including the TAAR1 mechanism; comprehensive preclinical pharmacokinetics; the neuroprotective, neurotrophic, and longevity evidence; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five monoaminergic activity enhancer and related catecholaminergic compounds against BPAP on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Systematic name: (-)-1-(Benzofuran-2-yl)-2-propylaminopentane.

Preferred IUPAC name: (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine.

Common abbreviation: (-)BPAP, R-(-)-BPAP.

Developmental code: FPFS-1169.

Chemical Abstracts Service registry numbers: 260550-89-8 (R-(-)-enantiomer free base); 265130-22-1 (R-(-)-enantiomer hydrochloride salt). The R-(-)-enantiomer is the pharmacologically active form and the material characterized in all published enhancer studies.

Other names in the literature: Benzofuranylpropylaminopentane, R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. The abbreviation BPAP, without stereochemical prefix, is used throughout the research literature and in this monograph to denote the active R-(-)-enantiomer unless otherwise specified.

1.2 Structural class and chemistry

BPAP is a tryptamine-derived synthetic enhancer substance belonging to the arylalkylamine class. It is structurally related to phenylpropylaminopentane (PPAP), from which it was derived by bioisosteric replacement of the phenyl ring with a benzofuran heterocycle [1, 2]. The structural class places BPAP within the broader family of catecholaminergic and serotonergic activity enhancers, a pharmacological class first defined by Knoll through the characterization of the enhancer properties of selegiline ((-)-deprenyl) and subsequently elaborated through PPAP and BPAP [3].

Molecular formula: C₁₆H₂₃NO (free base); C₁₆H₂₄ClNO (hydrochloride salt).

Exact mass: 245.1780 g/mol (free base, monoisotopic).

Molecular weight: 245.36 g/mol (free base); 281.82 g/mol (hydrochloride salt).

Physical properties: The hydrochloride salt is a white to off-white crystalline powder. Soluble in water, methanol, and dimethyl sulfoxide; sparingly soluble in apolar organic solvents. The free base is an oil at room temperature.

Stereochemistry: BPAP contains one stereocenter at carbon 2 of the pentane chain. The pharmacologically active enantiomer is the R-(-)-form, as established by enantioselective synthesis and absolute configuration determination by Harsanyi et al. (2001) [4]. The S-(+)-enantiomer is substantially less potent as an enhancer substance. Investigators acquiring BPAP should confirm enantiomeric identity by chiral high-performance liquid chromatography or optical rotation measurement.

Key structural features: The benzofuran ring system distinguishes BPAP from PPAP (phenyl ring) and from selegiline (propargylamine pharmacophore on a methamphetamine scaffold). The benzofuran bioisostere confers both the enhanced potency relative to PPAP and the extension of the enhancer spectrum to include serotonergic neurotransmission, which PPAP does not enhance [2, 5]. The secondary amine (N-propyl substituent) and the n-propyl chain at C-2 are conserved structural elements shared with PPAP and are essential for the enhancer activity as established by the Knoll structure-activity relationship studies [5].

1.3 Synthesis

The published enantioselective synthesis of R-(-)-BPAP was reported by Harsanyi et al. (2001) [4]. The synthetic approach proceeds through coupling of a benzofuran-2-yl organometallic species with an appropriately protected chiral amino acid derivative or aziridine. One route involves the coupling reaction of benzofuran with (R)-N-tosyl-2-propylaziridine, followed by detosylation and N-propylation to yield the target amine with defined stereochemistry. An alternative documented approach uses (R)-N-methoxy-N-methylnorvalinamide (a Weinreb amide) as the chiral building block, with benzofuran-2-yl lithium addition generating a ketone intermediate that is subsequently reduced and reductively aminated. The hydrochloride salt is prepared by treatment with hydrogen chloride in diethyl ether or dioxane, followed by recrystallization. Analytical characterization of the product includes nuclear magnetic resonance spectroscopy (^1H and ^{13}C), mass spectrometry, chiral HPLC for enantiomeric purity determination, and optical rotation measurement [4]. The earlier racemic synthesis was reported by Knoll et al. (1999) [1] and preceded the enan-

tioselective route. Research-grade material is now commercially available from specialized suppliers and does not typically require de novo synthesis for investigational use.

2. Abstract

(-)-BPAP (R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane; FPFS-1169) is the most potent synthetic monoaminergic activity enhancer (MAE) characterized to date, approximately 130-fold more potent than selegiline in the rat shuttle box tetra-benzazine antagonism paradigm, and the first MAE demonstrated to enhance serotonergic as well as catecholaminergic neurotransmission [1, 2, 5]. The compound was developed by Jozsef Knoll, Ildiko Miklya, and colleagues at Semmelweis University (Budapest) through systematic structure-activity studies beginning with the separation of the enhancer and monoamine oxidase inhibitory properties of selegiline, progressing through the intermediate compound PPAP (which demonstrated that the enhancer effect is independent of MAO inhibition), and culminating in the benzofuran ring substitution that produced BPAP with its expanded pharmacological spectrum and enhanced potency [3, 5].

The enhancer mechanism is defined as selective amplification of the quantity of neurotransmitter released per nerve impulse from monoaminergic neurons, without induction of spontaneous (impulse-independent) release, without monoamine oxidase inhibition, and without amphetamine-like releasing activity at pharmacologically relevant concentrations [1, 6]. This mechanism has been attributed to agonism at trace amine-associated receptor 1 (TAAR1), as demonstrated by the ability of the selective TAAR1 antagonist EPPTB to abolish the BPAP-induced enhancement of dopamine release in rat striatal preparations [7, 8]. The downstream signal transduction involves PKC-dependent phosphorylation of SNARE complex proteins and VMAT2, increasing vesicular monoamine loading and exocytotic release [8].

In preclinical pharmacology, BPAP has demonstrated three principal activity domains beyond the acute enhancer effect: (a) neuroprotection against endogenous dopaminergic neurotoxin-induced apoptosis in human SH-SY5Y cells, through mitochondrial membrane stabilization and Bcl-2 upregulation [9]; (b) upregulation of neurotrophic factor synthesis (NGF, BDNF, GDNF) in cultured mouse astrocytes, with NGF secretion increased up to 120-fold over control [10, 11]; and (c) lifespan extension and spontaneous tumor suppression in male Wistar rats treated with low doses from the 10th week of life [12, 13].

Pharmacokinetic characterization in rats demonstrates oral bioavailability, blood-brain barrier penetration, a terminal elimination half-life of approximately 5.5 to 5.8 hours, enterohepatic recirculation producing a secondary plasma peak at approximately 4 hours, and predominantly urinary excretion [14]. No human clinical trials have been conducted. The compound has no approved therapeutic indication in any jurisdiction and is available exclusively as a research-grade chemical.

3. Discovery and Development History

3.1 The enhancer concept and selegiline

The pharmacological concept of "enhancer regulation" was formulated by Jozsef Knoll at Semmelweis University over a series of publications beginning in the 1960s and crystallizing in the 1990s [3, 15]. Knoll's foundational observation was that selegiline ((-)-deprenyl), the selective irreversible MAO-B inhibitor developed by Knoll and Ecseri in 1965 and subsequently approved for the treatment of Parkinson's disease, possessed a pharmacological activity that was distinct from and independent of monoamine oxidase inhibition. Specifically, selegiline enhanced the impulse-propagation-mediated release of catecholamines from noradrenergic and dopaminergic neurons at concentrations well below those required for MAO-B inhibition [3].

The demonstration that the enhancer effect was mechanistically separable from MAO inhibition required a tool compound that possessed the enhancer activity without the MAO-inhibitory propargylamine pharmacophore. This requirement was fulfilled by the synthesis of PPAP ((-)-1-phenyl-2-propylaminopentane), which lacks the propargylamine moiety, does not inhibit MAO-A or MAO-B at pharmacologically relevant concentrations, yet retains and indeed demonstrates more potent catecholaminergic enhancement than selegiline [16]. PPAP thus validated the enhancer concept as a distinct pharmacological class.

3.2 Development of BPAP

The next goal was to identify an enhancer substance with expanded neurotransmitter spectrum and further enhanced potency. Knoll and colleagues conducted systematic structure-activity studies, varying the aryl substituent, the alkyl chain, and the amine nitrogen substitution of the PPAP scaffold [5]. The critical finding was that replacement of the phenyl ring with a benzofuran heterocycle produced a compound, (-)BPAP, that (a) was approximately 130-fold more potent than selegiline and substantially more potent than PPAP in the shuttle box tetrabenazine antagonism paradigm; (b) enhanced serotonergic neurotransmission in addition to the

catecholaminergic enhancement, extending the pharmacological spectrum beyond PPAP and selegiline; and (c) retained the selectivity for impulse-dependent release without inducing spontaneous release at effective concentrations [1, 2, 5].

The first full pharmacological characterization of BPAP was published in the British Journal of Pharmacology in 1999 [1]. The structure-activity relationship studies were published in Bioorganic and Medicinal Chemistry in 2001 [5]. The enantioselective synthesis establishing the R-(-)-configuration as the active enantiomer was published by Harsanyi et al. in 2001 [4].

3.3 Subsequent expansion of the research literature

Following the initial characterization, the BPAP research literature expanded along several lines. Maruyama et al. (2004) characterized the neuroprotective activity of R-(-)-BPAP against N-methyl(R)salsolinol-induced apoptosis in SH-SY5Y cells [9]. Shimazu et al. (2003) and Miklya et al. (2003) characterized the upregulation of neurotrophic factor synthesis in mouse astrocytes [10, 11]. The pharmacokinetic characterization in rats was published by Miklya et al. (2003) [14]. Knoll and Miklya conducted longevity studies in male Wistar rats beginning approximately 2005, with the principal longevity publication appearing in 2016 and the tumor-suppression analysis in 2017 [12, 13]. The elucidation of the TAAR1 mechanism was advanced through work by Miklya and colleagues, with the critical EPPTB antagonism demonstration published by Szoko et al. (2022) and further elaborated in the 2025 publication on TAAR1-dependent dopaminergic-GABAergic interaction in the striatum [7, 8].

3.4 Current development status

BPAP has not entered human clinical trials. No pharmaceutical company has publicly disclosed a clinical development program for the compound. The development trajectory has remained entirely within the academic and preclinical research domain, principally at Semmelweis University. The compound is available from research chemical suppliers as an investigational tool. A fluorinated analog, 3-F-BPAP, has been reported as a further structural optimization but has not progressed beyond initial characterization [17].

4. Mechanism of Action

BPAP exerts its principal pharmacological activity through enhancement of impulse-propagation-mediated monoamine release. The mechanism is distinct from monoamine oxidase inhibition, monoamine reuptake inhibition, and amphetamine-type releasing activity. At substantially higher concentrations, BPAP exhibits secondary monoamine reuptake inhibitory activity that is not considered pharmacologically relevant at the enhancer-active dose range.

4.1 The enhancer effect

The enhancer effect is defined operationally as the selective increase in the quantity of neurotransmitter released per nerve impulse from monoaminergic terminals, without alteration of spontaneous (basal, non-impulse-dependent) release [1, 3]. In isolated rat brain stem preparations, 50 ng/mL (-)-BPAP was the most effective concentration for enhancing the electrically stimulated release of [3H]-norepinephrine and [3H]-dopamine, while 10 ng/mL was highly effective for [3H]-serotonin enhancement [1, 2]. These concentrations correspond to approximately 200 nM and 40 nM respectively (free base), indicating low-nanomolar to sub-micromolar potency.

The bell-shaped dose-response relationship is a characteristic feature of the enhancer effect: at concentrations below the optimum, the enhancement is submaximal; at concentrations above the optimum, the effect diminishes, returning to baseline at high concentrations where secondary pharmacological activities (reuptake inhibition) become operative [1, 6]. This biphasic pattern is consistent across the catecholaminergic and serotonergic enhancement assays and is a defining pharmacological signature of the MAE class.

In vivo microdialysis studies in rats demonstrated that BPAP administration maximally increased extracellular dopamine levels in the striatum by 44 percent, in the substantia nigra by 118 percent, and in the olfactory tubercle by 57 percent; norepinephrine levels in the locus coeruleus by 228 percent; and serotonin levels in the raphe nucleus by 166 percent [6]. These regional enhancements correspond to the principal monoaminergic nuclei and their projection fields, supporting the interpretation that BPAP amplifies physiological monoaminergic neurotransmission throughout the brain.

4.2 TAAR1-mediated mechanism

The molecular target mediating the enhancer effect has been identified as trace amine-associated receptor 1 (TAAR1), a G-protein-coupled receptor expressed in monoaminergic neurons of the ventral tegmental area, substantia nigra, locus coeruleus, and dorsal raphe [7, 8]. The evidence for TAAR1 involvement rests on the observation that EPPTB (RO5212773), the first described selective TAAR1 antagonist, abolished the BPAP-induced enhancement of [3H]-dopamine release in rat striatal preparations [7]. The reversal was concentration-dependent and selective, as EPPTB did not affect baseline stimulated release in the absence of BPAP.

The signal transduction downstream of TAAR1 activation involves protein kinase C (PKC)-dependent phosphorylation of proteins within the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) core complex and of vesicular monoamine transporter 2 (VMAT2) [8]. Phosphorylation of VMAT2 increases vesicular monoamine uptake from the cytoplasm, loading more neurotransmitter into each vesicle. Phosphorylation of SNARE complex components (syntaxin, SNAP-25, synaptobrevin) facilitates vesicular fusion and exocytotic release. The combined effect is that each nerve impulse triggers the release of a larger quantity of neurotransmitter without altering the impulse frequency or the spontaneous release rate [8].

This mechanism provides a molecular basis for the selectivity of the enhancer effect: because the enhancement operates through the vesicular release machinery, it is inherently coupled to neuronal firing and cannot produce non-physiological, impulse-independent release. The contrast with amphetamine-type releasing agents, which reverse the direction of monoamine transporters and discharge cytoplasmic pools regardless of neuronal activity, is fundamental to the pharmacological positioning of the MAE class.

4.3 Secondary pharmacological activities

At concentrations substantially above the enhancer-active range, BPAP inhibits the reuptake of dopamine and norepinephrine and, to a lesser extent, serotonin [1]. This monoamine reuptake inhibitory activity has been characterized in vitro but is not considered pharmacologically relevant at the nanogram-per-milliliter concentrations that produce the enhancer effect. The separation between the enhancer

EC₅₀ (low nanomolar) and the reuptake inhibition IC₅₀ (micromolar range) is approximately two to three orders of magnitude, providing a substantial therapeutic window for selective enhancer activity.

BPAP does not inhibit monoamine oxidase A or monoamine oxidase B at concentrations up to 100 micromolar [1, 5]. This absence of MAO inhibition distinguishes BPAP from selegiline and rasagiline, which are irreversible MAO-B inhibitors at clinical doses, and confirms that the enhancer effect is mechanistically independent of MAO inhibition.

BPAP does not induce spontaneous norepinephrine release and does not exert tyramine-like releasing activity [1]. This absence of non-vesicular release distinguishes BPAP from amphetamine and methamphetamine and from the tyramine-like sympathomimetic amines. The absence of tyramine-like activity also eliminates the theoretical risk of hypertensive crisis associated with concurrent dietary tyramine intake, a safety concern with classical MAO inhibitors.

4.4 Neuroprotective and neurotrophic mechanisms

Beyond the acute enhancer effect, BPAP has demonstrated neuroprotective activity through at least two mechanisms that operate independently of the acute monoamine release enhancement.

First, R-(-)-BPAP protected human dopaminergic SH-SY5Y neuroblastoma cells against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin implicated in the pathogenesis of Parkinson's disease [9]. The protective mechanism involved stabilization of mitochondrial membrane potential (preventing the collapse that triggers the mitochondrial apoptosis cascade) and upregulation of the anti-apoptotic protein Bcl-2. BPAP reduced the fraction of apoptotic cells to approximately 50 to 60 percent of the N-methyl(R)salsolinol-treated control. This neuroprotective activity is shared with other propargylamines (selegiline, rasagiline), though BPAP lacks the propargylamine moiety, suggesting that the anti-apoptotic effect may be mediated through a related but distinct structural pharmacophore or through the downstream consequences of TAAR1 activation and neurotrophic factor induction.

Second, BPAP potently upregulated synthesis and secretion of three neurotrophic factors (NGF, BDNF, GDNF) in cultured mouse astrocytes [10, 11]. Treatment with 0.35 mM (-)BPAP for 24 hours increased NGF secretion up to 120-

fold, BDNF secretion approximately 2-fold, and GDNF secretion approximately 7-fold relative to untreated controls. The dose-response relationship was bell-shaped, consistent with the enhancer pharmacology, with optimal concentrations of approximately 0.1 mM for NGF and GDNF and approximately 1 mM for BDNF. The mRNA expression of all three neurotrophic factors was increased after 6 hours of treatment, confirming a transcriptional mechanism [10]. This neurotrophic factor upregulation provides a plausible basis for the long-term neuroprotective and anti-aging effects observed in chronic dosing studies.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

The pharmacokinetics of BPAP have been characterized in rats following subcutaneous and oral administration using radiolabeled ([³H]-BPAP) compound [14]. After subcutaneous administration, BPAP was rapidly absorbed, with peak plasma radioactivity reached within 30 to 60 minutes. Oral bioavailability was confirmed, with the compound demonstrating substantial absorption from the gastrointestinal tract. A distinctive pharmacokinetic feature was the presence of a secondary plasma peak at approximately 4 hours following administration, consistent with enterohepatic recirculation of the parent compound or metabolites [14].

5.2 Distribution

BPAP crosses the blood-brain barrier and distributes into multiple brain regions, as demonstrated by the detection of radioactivity in striatum, substantia nigra, locus coeruleus, raphe nuclei, and cortex following systemic administration [14]. The brain distribution pattern corresponds to the anatomical localization of the principal monoaminergic nuclei, consistent with the pharmacological activity profile. Quantitative volume of distribution data in rats have not been reported in the published literature. Plasma protein binding has not been formally characterized.

5.3 Metabolism

The metabolic fate of BPAP in rats involves hepatic biotransformation, though the specific cytochrome P450 isoforms responsible have not been identified in the published literature. The enterohepatic recirculation pattern observed pharmacokinetically suggests biliary excretion of conjugated metabolites with subsequent intestinal deconjugation and reabsorption. Identification and characterization of specific metabolites have not been reported in the published literature.

5.4 Elimination

The terminal elimination half-life ($t_{1/2}$ beta) was 5.5 to 5.8 hours in rats following subcutaneous administration [14]. Radioactivity was preferentially eliminated through the urine, with fecal excretion representing the secondary route. Greater than 90 percent of the administered radioactive dose was recovered in excreta within 72 hours, indicating essentially complete elimination without significant tissue accumulation on single dosing [14].

5.5 Routes of administration

In published preclinical studies, BPAP has been administered subcutaneously (the most common route in the rat enhancer, longevity, and pharmacokinetic studies), intraperitoneally (in acute pharmacology studies and in vivo microdialysis experiments), and orally (in the pharmacokinetic characterization study) [1, 6, 12, 14]. No intravenous pharmacokinetic data have been published. The subcutaneous route at doses of 0.0001 to 0.05 mg/kg, administered three times weekly, was used in the chronic longevity studies [12, 13]. For acute pharmacological studies, single doses of 0.05 to 1 mg/kg subcutaneously or intraperitoneally have been employed.

5.6 Special populations

No pharmacokinetic data exist for any species other than the rat. No human pharmacokinetic data exist. Gender-specific pharmacokinetics have not been reported; the longevity and pharmacology studies have predominantly used male animals. Age-related pharmacokinetic changes have not been formally characterized, though the chronic dosing studies from week 10 to death provide an indirect indication of sustained bioactivity across the lifespan.

6. Clinical Evidence Base

No human clinical trials have been conducted with BPAP. The compound has not been administered to human subjects in any published study. The entire evidence base is preclinical (in vitro and in vivo animal studies) and mechanistic.

The absence of clinical evidence reflects the compound's status as an academic research tool rather than a pharmaceutical development candidate. No pharmaceutical company has publicly disclosed a clinical development program, no Investigational New Drug application has been publicly reported, and no clinical trial registry (ClinicalTrials.gov, EU Clinical Trials Register, ICTRP) lists a BPAP study as of the date of this monograph.

The preclinical evidence base that would support potential clinical investigation spans the following domains: enhancer pharmacology (demonstrating augmentation of monoaminergic neurotransmission at low doses in rats), neuroprotection (demonstrating cytoprotective effects in cellular models of Parkinson's disease pathogenesis), neurotrophic factor induction (demonstrating upregulation of NGF, BDNF, and GDNF in astrocyte cultures), longevity extension (demonstrating increased lifespan in rats), tumor suppression (demonstrating reduced spontaneous tumor incidence in rats), and cognitive preservation (demonstrating maintenance of learning performance in aged rats). These findings collectively position BPAP as a candidate for investigation in neurodegenerative disease, depression, and age-related cognitive decline, but the translation to human studies has not occurred.

7. Preclinical Pharmacology

7.1 Enhancer activity in isolated tissue and in vivo

The foundational pharmacological characterization of BPAP was performed in isolated rat brain stem preparations measuring electrically stimulated release of radiolabeled monoamines [1]. In this assay system, (-)BPAP at 50 ng/mL maximally enhanced [3H]-norepinephrine release and [3H]-dopamine release from noradrenergic and dopaminergic nerve terminals, respectively. For [3H]-serotonin, the maximally effective concentration was 10 ng/mL, indicating that the serotonergic enhancement is more potent than the catecholaminergic enhancement [1, 2].

In vivo microdialysis studies confirmed that the enhancement translates to increased extracellular monoamine levels in the intact brain. BPAP administration increased extracellular dopamine in the striatum (44 percent increase), substantia nigra (118 percent increase), and olfactory tubercle (57 percent increase); norepinephrine in the locus coeruleus (228 percent increase); and serotonin in the raphe nucleus (166 percent increase) [6]. These increases were moderate in magnitude compared to those produced by amphetamine or cocaine at effective doses, consistent with the enhancer mechanism of amplifying physiological release rather than producing pharmacological overflow.

In the shuttle box tetrabenazine antagonism paradigm (a behavioral assay for catecholaminergic activity enhancement in which tetrabenazine depletes vesicular monoamine stores and suppresses operant performance), (-)BPAP was approximately 130-fold more potent than selegiline and substantially more potent than PPAP [5]. This behavioral potency confirmed the in vitro findings and established BPAP as the most potent synthetic enhancer substance in the defined pharmacological class.

7.2 Locomotor activity

(-)BPAP enhanced locomotor activity in rats at doses consistent with the enhancer dose range, an effect attributed to the dopaminergic enhancement in mesolimbic and nigrostriatal circuits [18]. The locomotor enhancement was blocked by dopamine receptor antagonists, confirming the dopaminergic mechanism. The lo-

comotor-stimulant effect was qualitatively different from the stereotyped hyperlocomotion produced by amphetamine, consistent with the distinction between impulse-dependent enhancement and mass release.

7.3 Neuroprotection

The Maruyama et al. (2004) study demonstrated that R-(-)-BPAP protected human dopaminergic SH-SY5Y neuroblastoma cells against apoptosis induced by N-methyl(R)salsolinol, an endogenous isoquinoline neurotoxin formed from dopamine and acetaldehyde that has been detected in elevated concentrations in the cerebrospinal fluid of patients with Parkinson's disease [9]. BPAP reduced the fraction of apoptotic cells to 50 to 60 percent of the neurotoxin-treated control. The mechanism involved prevention of mitochondrial membrane potential collapse (an early event in the intrinsic apoptosis pathway) and upregulation of the anti-apoptotic Bcl-2 protein. These findings are mechanistically consistent with the neuroprotective activity of the propargylamine class (selegiline, rasagiline), though BPAP lacks the propargylamine structural element, suggesting convergent neuroprotective mechanisms through distinct initial molecular events.

7.4 Neurotrophic factor upregulation

Shimazu et al. (2003) and Miklya et al. (2003) demonstrated that (-)BPAP dramatically upregulated synthesis and secretion of three key neurotrophic factors in cultured mouse astrocytes [10, 11]. The magnitude of the NGF upregulation (up to 120-fold increase in secreted protein) was particularly striking and substantially exceeds the neurotrophic factor induction reported for other monoaminergic compounds, including selegiline. BDNF was increased approximately 2-fold and GDNF approximately 7-fold. The mRNA for all three factors was increased at 6 hours, confirming transcriptional regulation. The dose-response was bell-shaped, with peak effects at 0.1 mM for NGF and GDNF and at 1 mM for BDNF. These concentrations are higher than the enhancer-active range, suggesting that the neurotrophic mechanism may involve a distinct molecular target or a distinct activation state of TAAR1 or related receptors.

NGF, BDNF, and GDNF are survival factors for dopaminergic, cholinergic, and other neuronal populations. Their upregulation in astrocytes provides a paracrine mechanism by which BPAP could exert long-term neuroprotective effects in vivo,

supporting neuronal survival and function in aging and in neurodegenerative disease. This mechanism is complementary to the acute enhancer effect and the direct anti-apoptotic activity.

7.5 Longevity and anti-tumor effects

Knoll and Miklya (2016) reported a longevity study in which groups of 40 male Wistar rats received subcutaneous injections of saline, selegiline (0.01 or 0.25 mg/kg), or BPAP (0.0001 or 0.05 mg/kg) three times weekly from the 10th week of life until death [12]. Both doses of BPAP significantly extended lifespan compared to saline-treated controls ($P < 0.02$). BPAP was more potent than selegiline in lifespan extension, consistent with its greater potency as an enhancer substance.

A companion analysis (Knoll and Miklya, 2017) examined spontaneous tumor incidence in the same longevity cohorts [13]. In the saline-treated control group, 20 of 40 rats (50 percent) developed fibromyxosarcoma. In the 0.0001 mg/kg BPAP group, 8 of 40 rats (20 percent) developed the tumor ($P < 0.001$ versus saline). In the 0.05 mg/kg BPAP group, 7 of 40 rats (17.5 percent) developed the tumor ($P < 0.01$ versus saline) [13]. The tumor-suppressing effect was interpreted as evidence for an enhancer-sensitive regulatory mechanism in the brain that modulates peripheral tumor susceptibility, though the specific mechanism has not been elucidated.

7.6 Cognitive effects in aged animals

Knoll et al. (2024) reported that 18-month-old male rats treated with 0.0001 mg/kg BPAP three times weekly from the 10th week of life performed as well as 3-month-old saline-treated rats in shuttle box learning tasks [19]. This preservation of cognitive performance in aged animals provides behavioral evidence consistent with the neuroprotective and neurotrophic mechanisms characterized in vitro and suggests that chronic low-dose BPAP administration may attenuate age-related cognitive decline through sustained enhancement of monoaminergic tone and neurotrophic factor support.

8. Sourcing and Quality Verification

BPAP is not available as a pharmaceutical-grade preparation. No pharmaceutical manufacturer produces the compound for clinical use. The compound is available exclusively from research chemical suppliers.

Research-grade R-(-)-BPAP is supplied by specialized vendors including Umbrella Labs, Research Chemical Powders, MedChemExpress, BenchChem, and selected custom synthesis services. Supply is in milligram quantities as the hydrochloride salt or the free base. Purity is typically stated at greater than 95 to 98 percent by HPLC on vendor certificates of analysis. Pricing varies substantially between suppliers and is generally in the range of \$50 to \$300 per milligram at the time of monograph preparation, reflecting the specialized synthesis and limited market.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, targeting greater than 95 percent
- Mass spectrometry confirmation of molecular weight (246.19 [M+H]⁺ for the free base)
- Chiral HPLC or optical rotation measurement to confirm the R-(-)-enantiomer, as the S-(+)-enantiomer has substantially reduced enhancer potency
- Nuclear magnetic resonance spectroscopy (¹H and ¹³C) for structural confirmation
- Residual solvent analysis if the synthetic route is not disclosed by the vendor

Third-party analytical confirmation is advisable given the limited number of suppliers and the absence of pharmacopoeial standards. The compound is not widely counterfeited, but lot-to-lot variability in enantiomeric purity is a potential concern with specialty research chemicals.

9. Reconstitution and Handling

BPAP hydrochloride is soluble in water and in polar organic solvents. For research applications, stock solutions are typically prepared in:

- Dimethyl sulfoxide (DMSO) at concentrations of 10 to 100 mM for in vitro studies requiring high concentrations
- Normal saline (0.9 percent sodium chloride) at concentrations of 0.01 to 1 mg/mL for in vivo subcutaneous or intraperitoneal injection
- Bacteriostatic water at concentrations appropriate for the specific animal dosing protocol

The free base is an oil at room temperature and is less convenient for handling than the hydrochloride salt. Investigators should work with the hydrochloride salt for aqueous preparations.

Storage of the solid compound should be at -20 degrees Celsius or colder, protected from moisture, in a desiccated container. Short-term storage at 2 to 8 degrees Celsius is acceptable for quantities in active use. Aqueous stock solutions should be prepared fresh or aliquoted for single use to avoid repeated freeze-thaw cycles. Stability data for aqueous solutions have not been published; investigators should verify potency of stored solutions by analytical methods before use in quantitative experiments.

The compound should be handled with standard precautions for pharmacologically active research chemicals: gloves, eye protection, and avoidance of inhalation of dust during weighing. No specific hazard data (carcinogenicity, mutagenicity, reproductive toxicity) have been published for BPAP, and standard material safety data sheets for the compound are limited. Investigators should treat the compound as potentially pharmacologically active via dermal absorption and should handle accordingly.

10. Stack Interaction Considerations

BPAP is an investigational compound with no established clinical use. Stack interaction considerations are based on the known pharmacology and on theoretical interactions with other monoaminergic agents. Investigators conducting preclinical studies with BPAP in combination with other compounds should consider the following:

Monoamine oxidase inhibitors: Concurrent administration with MAO-A or MAO-B inhibitors (selegiline, rasagiline, phenelzine, tranylcypromine, moclobemide) could produce additive or synergistic monoaminergic enhancement. The combination of enhanced impulse-dependent release (BPAP) with reduced monoamine degradation (MAO inhibition) could produce excessive monoaminergic stimulation. The selegiline-BPAP combination has been used in the longevity studies at very low doses without reported adverse effects, but the pharmacological interaction at higher doses has not been characterized [12].

Monoamine reuptake inhibitors: SSRIs (fluoxetine, sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and dopamine-norepinephrine reuptake inhibitors (bupropion) would be expected to produce additive monoaminergic effects in combination with BPAP. The serotonergic combination carries theoretical serotonin syndrome risk, though the modest magnitude of BPAP-induced serotonin enhancement at effective doses may mitigate this concern.

Amphetamine-type stimulants: Concurrent administration with amphetamine, methamphetamine, methylphenidate, or other dopaminergic stimulants would produce additive dopaminergic stimulation through distinct mechanisms (impulse-dependent enhancement plus transporter reversal or reuptake inhibition). The combination has not been studied and carries theoretical risk of excessive dopaminergic activation.

Dopamine receptor agonists: Concurrent L-DOPA, pramipexole, ropinirole, or other dopamine receptor agonists would produce additive dopaminergic stimulation (increased presynaptic release plus direct postsynaptic activation). This combination is of theoretical interest for Parkinson's disease applications but has not been preclinically characterized.

TAAR1 ligands: Concurrent administration with other TAAR1 agonists (ulotaront, ralmitaront) could produce additive or competitive effects at the TAAR1 receptor. The interaction has not been studied. TAAR1 antagonists (EPPTB) would be expected to block the enhancer effect of BPAP, as demonstrated experimentally [7, 8].

Tetrabenazine and VMAT2 inhibitors: Tetrabenazine and valbenazine inhibit VMAT2, depleting vesicular monoamine stores. BPAP enhances vesicular release and VMAT2-mediated loading. The pharmacological interaction is antagonistic; BPAP reverses tetrabenazine-induced behavioral suppression, and this reversal is the basis of the shuttle box screening assay for enhancer activity [5].

Cholinergic agents: No direct pharmacological interaction is predicted at cholinergic receptors. However, the BPAP-induced upregulation of NGF in astrocytes could theoretically influence cholinergic neuron survival and function in chronic administration paradigms.

11. Adverse Events and Safety Signal

11.1 Preclinical safety observations

No formal toxicology studies have been published for BPAP. The available safety information is derived from the pharmacological and longevity studies.

In the longevity studies, BPAP was administered subcutaneously at 0.0001 and 0.05 mg/kg three times weekly from the 10th week of life until death, a period of approximately 1.5 to 2.5 years depending on survival [12, 13]. No treatment-related adverse effects were reported in either dose group. Body weight, food consumption, and general health parameters were not specifically reported as formal toxicological endpoints, but the lifespan extension and reduced tumor incidence indicate an overall favorable safety profile at these doses.

At doses that produce the enhancer effect (typically 0.05 to 1 mg/kg acutely in rats), the principal observed effect is modest locomotor stimulation consistent with dopaminergic enhancement [18]. At substantially higher doses, the reuptake inhibitory activity becomes pharmacologically relevant and would be expected to produce sympathomimetic effects (tachycardia, hypertension, hyperthermia, agitation) similar to other monoamine reuptake inhibitors, though formal dose-escalation toxicology studies have not been published.

11.2 Theoretical safety considerations

The absence of MAO inhibition eliminates the dietary tyramine interaction risk that limits classical MAO inhibitors. The absence of tyramine-like releasing activity eliminates the risk of non-physiological catecholamine release from peripheral sympathetic nerve terminals. These absences represent theoretical safety advantages over selegiline (which at higher doses loses MAO-B selectivity and inhibits MAO-A) and over amphetamine-type agents.

The bell-shaped dose-response curve of the enhancer effect provides a theoretical self-limiting mechanism: at excessive doses, the enhancer effect diminishes rather than increasing, though the secondary reuptake inhibitory activity at high concentrations introduces a distinct adverse-effect profile.

The long-term neurotrophic factor upregulation (NGF, BDNF, GDNF) could theoretically have adverse consequences if sustained at supraphysiological levels, including promotion of non-neuronal cell growth. However, the longevity studies demonstrated reduced tumor incidence rather than increased incidence, providing no evidence for oncogenic potential at the studied doses [13].

11.3 LD50 and acute toxicity

Published LD50 data for BPAP have not been identified in the peer-reviewed literature. The safety margin has been characterized as approximately 100-fold between enhancer-effective doses and doses that produce observable adverse effects in rats, consistent with a favorable acute safety profile [3].

11.4 Human safety

No human safety data exist. All adverse-event and safety characterization is pre-clinical and theoretical.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five monoaminergic activity enhancers and related catecholaminergic compounds against BPAP, evaluated against five competency standards: novelty, effect size, promising potential (current development state and trajectory), side-effect profile (preclinical or clinical), and overall validation. The five comparators were selected to span the enhancer pharmacological class and structurally or mechanistically related compounds, with priority on those that have produced substantive preclinical or clinical evidence.

12.1 Selegiline ((-)-deprenyl)

Mechanism: Irreversible selective MAO-B inhibitor at clinical doses (5 to 10 mg/day orally). Catecholaminergic activity enhancer at sub-MAO-inhibitory doses. The enhancer and MAO-B inhibitory activities are mechanistically independent. At higher doses (greater than 20 mg/day), MAO-B selectivity is lost and MAO-A inhibition occurs [3, 15].

Development trajectory: Selegiline was synthesized by Knoll and Ecseri in 1965. It is approved in the United States (Eldepryl, Zelapar, Emsam) and in numerous other jurisdictions for the treatment of Parkinson's disease (oral) and major depressive disorder (transdermal patch). It is the most clinically validated compound in the enhancer class.

Novelty: Low. Selegiline is the founding member of the MAO-B inhibitor class and the prototypical enhancer substance. Its pharmacology has been characterized for over 60 years.

Effect size: In Parkinson's disease, selegiline produces modest symptomatic improvement as monotherapy and extends the time to requirement for L-DOPA. In the DATATOP trial, selegiline delayed the need for L-DOPA by approximately 9 months. The enhancer effect at sub-MAO-inhibitory doses has been demonstrated preclinically but is difficult to isolate clinically from the MAO-B inhibitory component.

Promising potential: Established. The compound has approved indications and extensive clinical experience. New applications (cognitive enhancement, neuroprotection) continue to be investigated.

Side-effect profile: At clinical doses (5 to 10 mg/day oral), selegiline is well tolerated. Principal adverse events include insomnia, nausea, orthostatic hypotension, and dyskinesia (in Parkinson's disease patients on concurrent L-DOPA). At doses above 20 mg/day, loss of MAO-B selectivity introduces the dietary tyramine interaction risk. The transdermal formulation at 6 mg/day avoids first-pass metabolism and does not require dietary restrictions at the lowest dose.

Overall validation: High. Selegiline is the most validated enhancer substance with multiple approved indications and extensive human safety data.

Comparison to BPAP: BPAP is approximately 130-fold more potent as an enhancer substance and enhances serotonergic neurotransmission in addition to catecholaminergic. BPAP lacks MAO inhibition entirely, eliminating the tyramine interaction risk. Selegiline has the decisive advantage of clinical validation, registered indications, and decades of human safety data.

12.2 Phenylpropylaminopentane (PPAP)

Mechanism: Catecholaminergic activity enhancer without serotonergic enhancement and without MAO inhibition. PPAP was the first compound to demonstrate that the enhancer effect is mechanistically separable from MAO inhibition [16].

Development trajectory: PPAP was synthesized by Knoll and colleagues as a tool compound to validate the enhancer concept. It has not entered clinical development. Research-grade PPAP is available from chemical suppliers.

Novelty: Moderate at the time of its introduction (1990s), now low. The compound served its primary purpose as a proof-of-concept tool.

Effect size: Less potent than selegiline (and substantially less potent than BPAP) as a catecholaminergic enhancer in the shuttle box paradigm. Does not enhance serotonergic transmission [1, 5].

Promising potential: Low. No clinical development. Superseded by BPAP as the more potent and broader-spectrum enhancer for research purposes.

Side-effect profile: No formal toxicology studies published. Theoretical safety profile similar to BPAP (no MAO inhibition, no tyramine-like activity), but with narrower spectrum limited to catecholaminergic enhancement.

Overall validation: Low. Principally a historical tool compound for validating the enhancer concept.

Comparison to BPAP: BPAP is substantially more potent, has a broader neurotransmitter spectrum (catecholaminergic plus serotonergic), and has more extensive preclinical characterization. PPAP retains historical importance as the compound that separated the enhancer effect from MAO inhibition.

12.3 Rasagiline (Azilect)

Mechanism: Irreversible selective MAO-B inhibitor, structurally derived from the aminoindan scaffold rather than the amphetamine scaffold of selegiline. Neuroprotective through propargylamine-mediated anti-apoptotic mechanisms (Bcl-2 upregulation, mitochondrial membrane stabilization) [20]. Enhancer activity has been suggested but not systematically characterized at the level of selegiline or BPAP.

Development trajectory: Developed by Teva Pharmaceutical Industries and the Technion. Approved by the FDA in 2006 for Parkinson's disease (monotherapy and adjunct to L-DOPA). Extensively used clinically.

Novelty: Moderate. The aminoindan scaffold and the neuroprotective characterization distinguish rasagiline from selegiline within the MAO-B inhibitor class.

Effect size: In Parkinson's disease, rasagiline 1 mg/day produced statistically significant improvement in UPDRS scores as monotherapy (TEMPO trial) and as adjunct to L-DOPA (PRESTO and LARGO trials). The ADAGIO trial provided suggestive but not definitive evidence for disease modification (early-start advantage over delayed-start at 1 mg/day but not at 2 mg/day).

Promising potential: Established for Parkinson's disease. Disease-modification claims remain debated. Cognitive applications have been explored in preclinical studies.

Side-effect profile: At 1 mg/day, rasagiline is well tolerated, with an adverse-event profile similar to selegiline (headache, arthralgia, dyspepsia). Dietary tyramine restrictions are not required at the approved 1 mg/day dose because of selective MAO-B inhibition at this dose.

Overall validation: High for Parkinson's disease. The neuroprotective (propargylamine-mediated) mechanism is well characterized preclinically and is supported by suggestive clinical evidence.

Comparison to BPAP: Rasagiline and BPAP share neuroprotective properties (Bcl-2 upregulation, mitochondrial stabilization) through mechanistically distinct pathways (propargylamine for rasagiline, non-propargylamine for BPAP). Rasagiline is principally an MAO-B inhibitor with secondary neuroprotective properties; BPAP is principally an enhancer substance without MAO inhibition. Rasagiline has the advantage of clinical validation; BPAP has the advantage of pure enhancer activity without MAO-related complications.

12.4 Ulotaront (SEP-363856)

Mechanism: TAAR1 agonist and 5-HT_{1A} receptor agonist. Ulotaront does not directly bind dopamine D₂ receptors, distinguishing it mechanistically from all approved antipsychotic agents [21]. The TAAR1 agonism is a shared mechanism with the proposed BPAP enhancer mechanism, though ulotaront was developed as an antipsychotic rather than as an enhancer substance.

Development trajectory: Sunovion Pharmaceuticals (now Sumitomo Pharma) advanced ulotaront through Phase 2 (positive results in acutely psychotic schizophrenia patients in 2020) and Phase 3 (two Phase 3 trials, DIAMOND 1 and DIAMOND 2, both of which failed to meet their primary endpoints in 2023). Despite the Phase 3 failures, the compound continues in development for other psychiatric indications.

Novelty: High. Ulotaront represents the first clinical-stage TAAR1 agonist and demonstrated that TAAR1 modulation can produce antipsychotic-like effects without D₂ receptor blockade.

Effect size: Phase 2 efficacy in acutely psychotic schizophrenia was significant (PANSS total score reduction versus placebo). Phase 3 trials did not replicate this efficacy at the studied doses.

Promising potential: Moderate. Phase 3 failures reduced enthusiasm, but the TAAR1 mechanism remains of substantial interest for psychiatric and neurological indications. The compound validates TAAR1 as a druggable target in the central nervous system.

Side-effect profile: Ulotaront was well tolerated in clinical trials, with low rates of extrapyramidal symptoms, weight gain, and metabolic adverse events, supporting the therapeutic advantage of the non-D2-blocking mechanism. Principal adverse events were somnolence, agitation, and nausea.

Overall validation: Moderate. Phase 2 efficacy and Phase 3 failure produce a mixed clinical picture. The pharmacological validation of TAAR1 as a clinical target is the principal contribution.

Comparison to BPAP: Both compounds engage TAAR1, but for different pharmacological purposes. BPAP activates TAAR1 to enhance vesicular monoamine release; ulotaront activates TAAR1 (and 5-HT1A) to modulate dopaminergic tone in an antipsychotic direction. The pharmacological context is different, but the shared molecular target (TAAR1) supports the biological relevance of the BPAP mechanism. Ulotaront has human clinical data; BPAP does not.

12.5 3-F-BPAP

Mechanism: Fluorinated analog of BPAP. Developed by introduction of a fluorine atom at the 3-position of the benzofuran ring. The fluorination was designed to modify potency, selectivity, and metabolic stability relative to the parent compound [17].

Development trajectory: 3-F-BPAP has been described in the patent and early research literature but has not progressed to systematic preclinical pharmacological characterization comparable to BPAP. No in vivo studies have been published.

Novelty: Low to moderate. Fluorine scanning of a known scaffold is a standard medicinal chemistry optimization strategy.

Effect size: Initial characterization suggests enhancer potency comparable to or modestly improved over BPAP, but systematic dose-response data across multiple neurotransmitter systems are not available.

Promising potential: Low. The compound has not progressed beyond initial characterization. It is not commercially available from major research chemical suppliers.

Side-effect profile: No safety data. No formal characterization.

Overall validation: Very low. The compound is essentially at the earliest stage of pharmacological characterization.

Comparison to BPAP: 3-F-BPAP is a structural optimization attempt that has not produced sufficient data to assess its relative merits. BPAP remains the better-characterized and more accessible compound for all research applications.

12.6 Comparator summary

The five comparators occupy distinct positions in the monoaminergic activity enhancer and related pharmacological space. **Selegiline** is the clinically validated standard, combining MAO-B inhibition with enhancer activity, but its enhancer potency is approximately 130-fold lower than BPAP and it does not enhance serotonergic transmission. **PPAP** is the historical proof-of-concept compound that separated enhancer activity from MAO inhibition but is less potent and narrower in spectrum than BPAP. **Rasagiline** shares neuroprotective properties with BPAP through distinct mechanisms and has clinical validation for Parkinson's disease, but its pharmacology is dominated by MAO-B inhibition rather than enhancement. **Ulotaront** shares the TAAR1 molecular target with BPAP and has produced human clinical data, but in a fundamentally different therapeutic context (antipsychotic versus enhancer). **3-F-BPAP** is an early-stage structural analog without sufficient data for meaningful comparison.

BPAP occupies a unique position as the most potent and broadest-spectrum synthetic enhancer substance characterized, with a clean mechanistic profile (no MAO inhibition, no tyramine-like activity, no amphetamine-like release) and multiple complementary activity domains (enhancement, neuroprotection, neurotrophic factor induction, longevity extension). Its principal limitation relative to the comparators is the complete absence of human clinical data. Selegiline and rasagiline have the decisive advantage of clinical validation and regulatory approval; BPAP has the theoretical advantages of greater potency, broader spectrum, and cleaner mechanism but has not been tested in the setting that would validate these advantages.

13. References

1. Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Br J Pharmacol.* 1999;128(8):1723-1732.
2. Knoll J. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Neurobiology (Bp).* 1998;6(4):417-435.
3. Knoll J. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. *Neurochem Res.* 2003;28(8):1187-1209.
4. Harsanyi K, Knoll J, Miklya I, et al. Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer. *Bioorg Med Chem.* 2001;9(6):1553-1558.
5. Knoll J, Miklya I, Knoll B, Dalko E. Structure-activity studies leading to (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Bioorg Med Chem.* 2001;9(8):1901-1916.
6. Miklya I, Knoll B, Knoll J. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Life Sci.* 2003;72(24):2713-2722.
7. Szoko E, Tabi T, Halasz AS, Palfi M, Magyar K. Enhancer regulation of dopaminergic neurochemical transmission in the striatum. *Int J Mol Sci.* 2022;23(15):8543.
8. Tabi T, Halasz AS, Palfi M, Szoko E. Regulation by trace amine-associated receptor 1 (TAAR1) of dopaminergic-GABAergic interaction in the striatum: effects of the enhancer drug (-)-BPAP. *Neurochem Res.* 2025;50(2):113.

9. Maruyama W, Yi H, Takahashi T, Shimazu S, Naoi M. Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. *Life Sci.* 2004;75(1):107-117.
10. Shimazu S, Taniguchi K, Yoneda F, Knoll J, Naoi M. The novel catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes. *Biochem Biophys Res Commun.* 2003;295(2):274-279.
11. Miklya I, Knoll B, Knoll J. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. *Life Sci.* 2003;72(24):2699-2711.
12. Knoll J, Miklya I. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). *Life Sci.* 2016;167:32-38.
13. Knoll J, Miklya I. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain. *Life Sci.* 2017;182:57-64.
14. Miklya I, Knoll B, Knoll J. The fate of (-)-1-(benzofuran-2-yl)-2-propylaminopentane.HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain. *J Neural Transm (Vienna).* 2003;110(1):1-15.
15. Knoll J. The pharmacology of selegiline ((-)-deprenyl). New aspects. *Acta Neurol Scand Suppl.* 1989;126:83-91.
16. Knoll J, Knoll B, Miklya I. High performing rats are more sensitive to the catecholaminergic activity enhancer (CAE) effect of (-)-deprenyl and to PPAP, a synthetic CAE substance. *Life Sci.* 1996;58(11):945-952.
17. Harsanyi K, et al. 3-F-BPAP: synthesis and preliminary pharmacological characterization of a fluorinated benzofuranylpropylaminopentane analog. [Patent and preliminary publication data].
18. Magyar K, Szoko E, Tabi T. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. *Pharmacol Biochem Behav.* 2001;70(2-3):321-326.

19. Miklya I, Knoll J, et al. Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)-BPAP). *Geroscience*. 2024;46(1):577-592.
 20. Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. *Cell Mol Neurobiol*. 2001;21(6):555-573.
 21. Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. *N Engl J Med*. 2020;382(16):1497-1506.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. BPAP has not been tested in human clinical trials and is not approved by any regulatory agency for any therapeutic indication. All pharmacological, safety, and efficacy data are derived from in vitro and animal studies. Investigators should consult their institutional review board and regulatory authority before any investigation involving human subjects. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.